These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 29688797

  • 21. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.
    Kang B, Lee Y, Lee K, Choi YO, Choe YH.
    Inflamm Bowel Dis; 2018 Feb 15; 24(3):607-616. PubMed ID: 29390113
    [Abstract] [Full Text] [Related]

  • 22. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH.
    Inflamm Bowel Dis; 2021 Nov 15; 27(12):1954-1962. PubMed ID: 33538298
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK, NOR-SWITCH study group.
    Lancet; 2017 Jun 10; 389(10086):2304-2316. PubMed ID: 28502609
    [Abstract] [Full Text] [Related]

  • 27. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.
    Expert Opin Biol Ther; 2019 Oct 10; 19(10):1023-1030. PubMed ID: 30601098
    [Abstract] [Full Text] [Related]

  • 28. CT-P13: design, development, and place in therapy.
    Gabbani T, Deiana S, Annese V.
    Drug Des Devel Ther; 2017 Oct 10; 11():1653-1661. PubMed ID: 28652703
    [Abstract] [Full Text] [Related]

  • 29. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH.
    J Comp Eff Res; 2017 Nov 10; 6(8):693-712. PubMed ID: 29172717
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
    Ebada MA, Elmatboly AM, Ali AS, Ibrahim AM, Fayed N, Faisal AF, Alkanj S.
    Int J Colorectal Dis; 2019 Oct 10; 34(10):1633-1652. PubMed ID: 31492986
    [Abstract] [Full Text] [Related]

  • 36. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N, Abitbol V, Tannoury J, Lecomte M, Assaraf J, Malamut G, Gagnière C, Barré A, Sobhani I, Chaussade S, Amiot A.
    Aliment Pharmacol Ther; 2021 Apr 10; 53(8):887-899. PubMed ID: 33647174
    [Abstract] [Full Text] [Related]

  • 37. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S, Piazza O Sed N, Conforti FS, Fascì A, Rimondi A, Marinoni B, Casini V, Ricci C, Munari F, Pirola L, Invernizzi P, Girelli C, Lupinacci G, Pastorelli L, Cavallaro F, Ferraris L, Colucci A, Amato A, Eugenio Tontini G, Vecchi M, Fiorino G, Caprioli F.
    Clin Transl Sci; 2022 Jan 10; 15(1):172-181. PubMed ID: 34523800
    [Abstract] [Full Text] [Related]

  • 38. Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease.
    Bernard EJ, Fedorak RN, Jairath V.
    Dig Dis Sci; 2020 Aug 10; 65(8):2354-2372. PubMed ID: 31970610
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.